Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Immunoassay Market - 2019-2026

Published by DataM Intelligence Product code 812773
Published Content info
Delivery time: 1-2 business days
Back to Top
Global Immunoassay Market - 2019-2026
Published: March 1, 2020 Content info:

Global Immunoassay Market Overview

Immunoassay are biotechnological methods in which the quantification of the analyte depends on the reaction of an antigen and an antibody. Ideally, these methods are based on the competitive binding reaction between a fixed amount labeled form of an analyte and a variable amount of unlabeled sample analyte for a limited amount of binding sites on a highly specific anti-analyte antibody. Immunoassays have widely used in disease diagnosis, therapeutic drug monitoring, clinical pharmacokinetic, bioequivalence studies in drug discovery and pharmaceutical industries. The importance and widespread of immunoassay methods in the pharmaceutical analysis are attributed to their inherent specificity, high-throughput, and high sensitivity for the analysis of a wide range of analytes in biological samples.

The global immunoassay market was worth $XX billion in 2018 and is forecasted to reach $XX billion by 2026, at a CAGR of XX% during the forecast period.

Market Drivers:

Increase in the prevalence of infectious diseases and chronic diseases and an increase in extensive usage of immunoassay in oncology are driving the global immunoassay market during the forecast. The growth in biotechnology and biopharmaceutical industries are additionally contributing to the growth in the global immunoassay market.

According to WHO in 2017, the annual epidemics in seasonal influenza globally estimated that 3-5 million cases of severe illness and about 290,000-600,000 respiratory deaths are observed and it is also estimated the epidemiology might increase in coming years.

According to the World Health organization in 2017, there were 110,000 measles deaths globally and prevalence ratio is highest among children under the age of five.


Major factors hindering the global Immunoassay market during the forecast period are highly associated with technology compared with conventional technology.

Market Segmentation

Global Immunoassay market is segmented by technology, by type, by end users, and by the application. By technology, it includes radioimmunoassay, fluorescence immunoassay, nephelometric immunoassay, enzyme immunoassay, chemiluminescence immunoassay, and others, and by type multiplexed immunoassay, and single immunoassay. The end users segment includes academic institutions, centralized laboratories, hospitals, contract research organizations, pharma & biotech companies, and others, and application segment includes autoimmune disorders, cardiology, endocrinology, oncology, toxicology testing, hematology & blood screening, infectious diseases, drug monitoring, neonatal screening, and others.

Chemiluminescence immunoassay segment dominates the global immunoassay market during the forecast period due to low cost and high sensitivity associated with the Chemiluminescence Assay and wider portfolio.

Currently, Chemiluminescence immunoassay offers one of the best solutions the quantification of the complex mixture with low concentration. The non-radioactive nature of the assay allows them to replace in many radioimmunoassay application with varied discipline it includes agriculture, microbiology, therapeutic medicine and etc.,

In terms of technology trends, the market is increasingly adopting the chemiluminescence immunoassay analyzers which replaces the older versions of immunoassays while some labs still operate on immunofluorescence and semi-automated CLIA systems.

Global Immunoassay Market - Geographical Analysis

The global immunoassay market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

North America dominates the global Immunoassay market during the forecast period it is valued at USD xx Mn in 2018 and estimated to grow at CAGR of xx%.

The growth of the North America Immunoassay market is mainly attributed to the increased healthcare expenditure, awareness among the disease population across the region regarding the immunoassay testing and increase in the incidence of chronic and infectious diseases and the growth is expected to remain high during the forecast period.

According to a study by researchers at national instate of health in 2018 estimated, approximately 45% or 133 million of all Americans suffer from at least one form of chronic disease and number is growing.

Global Immunoassay Market - Competitive Analysis

New product launch with advanced technology, FDA approval and 510(K) clearance by key players are driving the global Immunoassay market during the forecast period.

In October 2018, Abbott received U.S. Food and Drug Administration (FDA) clearance for its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing.

In September 2017, ArcticZymes has today launched its SAN HQ ELISA immunoassay product which is targeted towards the bio-manufacturing market.

In February 2017, BioMerieux received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of VIDAS B*R*A*H*M*S PCT, an automated assay measuring procalcitonin (PCT) levels.

Major market players in the immunoassay market are Devon medical products, Akers biosciences, inc., Hologic (gen-probe), Biomerieux, Danaher Corporation (Beckman coulter), Abbott laboratories, inc, EDP biotech corporation, Becton & Dickinson and company, Intrinsic lifesciences LLC, Aegean immunoassays sa

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Table of Contents

Table of Contents


  • 1.1. Research Methodology
  • 1.2. The Scope of the market



  • 3.1. Drivers
  • 3.2. Restraints
  • 3.3. Impact analysis
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Patent Analysis


    • 4.1.1. Radio Immunoassay
    • 4.1.2. Fluorescence Immunoassay
    • 4.1.3. Nephelometric Immunoassay
    • 4.1.4. Enzyme Immunoassay
    • 4.1.5. Chemiluminescence Immunoassay
    • 4.1.6. Others
  • 4.2. BY TYPE
    • 4.2.1. Multiplexed Immunoassay
    • 4.2.2. Single Immunoassay
  • 4.3. BY END USERS
    • 4.3.1. Academic Institutions
    • 4.3.2. Centralized Laboratories
    • 4.3.3. Hospitals
    • 4.3.4. Contract Research Organizations
    • 4.3.5. Pharma & Biotech
    • 4.3.6. Others
    • 4.4.1. Autoimmune Disorders
    • 4.4.2. Cardiology
    • 4.4.3. Endocrinology
    • 4.4.4. Oncology
    • 4.4.5. Toxicology testing
    • 4.4.6. Hematology & blood screening
    • 4.4.7. Infectious diseases
    • 4.4.8. Drug Monitoring
    • 4.4.9. Neonatal Screening
    • 4.4.10. Others


  • 5.1. Geographic Overview
  • 5.2. North America
    • 5.2.1. The U.S.
    • 5.2.2. Mexico
    • 5.2.3. Canada
  • 5.3. Europe
    • 5.3.1. Germany
    • 5.3.2. The U.K.
    • 5.3.3. France
    • 5.3.4. Italy
    • 5.3.5. Spain
    • 5.3.6. Rest of Europe
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5. Asia Pacific
    • 5.5.1. China
    • 5.5.2. India
    • 5.5.3. Japan
    • 5.5.4. Australia
    • 5.5.5. Rest of Asia Pacific
  • 5.6. Rest of World


  • 6.1. Competitive Scenario
  • 6.2. Heat Map Analysis
  • 6.3. Product Benchmarking


  • 7.1. Devon Medical Products
  • 7.2. Akers Biosciences, Inc.
  • 7.3. Hologic (Gen-Probe)
  • 7.4. Biomerieux
  • 7.5. Danaher Corporation (Beckman Coulter)
  • 7.6. Abbott Laboratories, Inc
  • 7.7. EDP Biotech Corporation
  • 7.8. Becton, Dickinson And Company
  • 7.9. Intrinsic Lifesciences LLC
  • 7.10. Aegean Immunoassays SA

8. Key companies to watch

9. Emerging Companies


  • 10.1. Sources
  • 10.2. List of Tables
  • 10.3. Expert Panel Validation
  • 10.4. Disclaimer
  • 10.5. Contact Us
Back to Top